Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Real-World Treatment (Tx) Patterns and Clinical Outcomes Among Patients (Pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Received at Least 2 Prior Lines of Therapy Including Bruton Tyrosine Kinase Inhibitor (BTKi) and/or B-Cell Lymphoma 2 Inhibitor (BCL2i)

Farrukh T. Awan, Gaurav A. Deshpande, Trong Kim Le, Sean Garrison, Simran K. Tiwana, Masoom Priyadarshini

Blood (2022) 140 (Supplement 1): 7028–7029.

https://doi.org/10.1182/blood-2022-159195

Published: 2022

Journal Articles

Real-World Treatment Patterns and Costs of Chimeric Antigen Receptor (CAR) T Cell Therapies, Polatuzumab Vedotin-Piiq (Pola), and Tafasitamab-Cxix (Tafa) in Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Fei Fei Liu, Krishnaveni Subbiah, Tao Gu, Trong Kim Le

Blood (2022) 140 (Supplement 1): 2414–2415.

https://doi.org/10.1182/blood-2022-162587

Published: 2022

Journal Articles

Real-World Experience with Anemia and Iron Overload Therapies in Myelodysplastic Syndromes (MDS): Treatment Sequence, Duration, and Patient Compliance

Krystal Huey, Ruizhi Zhao, Tao Gu, Trong Kim Le, Shalon Jones, Luciana Bueno, Derek Tang

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-136684

Published: 2020

Journal Articles

Prevalence of Comorbidities Relevant to the Choice of Second-Generation (2-G) Tyrosine Kinase Inhibitor (TKI) for the Treatment of Chronic Myeloid Leukemia (CML) in the United States Using Real-World Claims Databases

Elias J. Jabbour, MD, Min You, MS, Trong Kim Le, MPH, MS, John Brokars, MS, Alexander Brun, PharmD, Dinara Makenbaeva, MD MBA

Blood (2018) 132 (Supplement 1): 4265.

https://doi.org/10.1182/blood-2018-99-113568

Published: 2018

Journal Articles

Outcomes of Classical Hodgkin Lymphoma in US Hematology Practices: Initial Data from a Prospective Real-World Study

Christopher A. Yasenchak, MD, Jakub Svoboda, MD, Sarah M Larson, MD, Don A Stevens, MD, Srikanth Gajavelli, MD, Trong Kim Le, Philippe Armand, MD PhD

Blood (2017) 130 (Supplement 1): 5626.

https://doi.org/10.1182/blood.V130.Suppl_1.5626.5626

Published: 2017

NARROW

Real-World Treatment (Tx) Patterns and Clinical Outcomes Among Patients (Pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Received at Least 2 Prior Lines of Therapy Including Bruton Tyrosine Kinase Inhibitor (BTKi) and/or B-Cell Lymphoma 2 Inhibitor (BCL2i)

Real-World Treatment Patterns and Costs of Chimeric Antigen Receptor (CAR) T Cell Therapies, Polatuzumab Vedotin-Piiq (Pola), and Tafasitamab-Cxix (Tafa) in Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Real-World Experience with Anemia and Iron Overload Therapies in Myelodysplastic Syndromes (MDS): Treatment Sequence, Duration, and Patient Compliance

Prevalence of Comorbidities Relevant to the Choice of Second-Generation (2-G) Tyrosine Kinase Inhibitor (TKI) for the Treatment of Chronic Myeloid Leukemia (CML) in the United States Using Real-World Claims Databases

Outcomes of Classical Hodgkin Lymphoma in US Hematology Practices: Initial Data from a Prospective Real-World Study

Email alerts

ASH Publications

American Society of Hematology

Real-World Treatment (Tx) Patterns and Clinical Outcomes Among Patients (Pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Received at Least 2 Prior Lines of Therapy Including Bruton Tyrosine Kinase Inhibitor (BTKi) and/or B-Cell Lymphoma 2 Inhibitor (BCL2i)

Real-World Treatment Patterns and Costs of Chimeric Antigen Receptor (CAR) T Cell Therapies, Polatuzumab Vedotin-Piiq (Pola), and Tafasitamab-Cxix (Tafa) in Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Real-World Experience with Anemia and Iron Overload Therapies in Myelodysplastic Syndromes (MDS): Treatment Sequence, Duration, and Patient Compliance

Prevalence of Comorbidities Relevant to the Choice of Second-Generation (2-G) Tyrosine Kinase Inhibitor (TKI) for the Treatment of Chronic Myeloid Leukemia (CML) in the United States Using Real-World Claims Databases

Outcomes of Classical Hodgkin Lymphoma in US Hematology Practices: Initial Data from a Prospective Real-World Study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only